The Role of Epidermal Growth Factor Receptor (EGFR) and the Downstream Gene KRAS in Pancreatic Cancer Patients Receiving Gemcitabine Combined With Erlotinib Therapy

Trial Profile

The Role of Epidermal Growth Factor Receptor (EGFR) and the Downstream Gene KRAS in Pancreatic Cancer Patients Receiving Gemcitabine Combined With Erlotinib Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top